Results 21 to 30 of about 7,827 (211)
Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin +5 more
doaj +1 more source
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression [PDF]
BackgroundBipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated.
Di Nicola, M +4 more
core +4 more sources
Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review [PDF]
Background: This study evaluated efficacy and safety of intravenous subanesthetic doses of esketamine using an administration time of 10 minutes in patients with treatment-resistant depression and bipolar depression. Methods: A retrospective chart review
Quarantini, Lucas C. +20 more
core +2 more sources
Craving and addictive potential of esketamine as side effects?
Introduction: Esketamine was approved for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant, and for treating depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Orsolini, Laura +5 more
core +1 more source
Esketamine for treatment-resistant depression in adults
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression.
Barbui C. +7 more
core +2 more sources
Introduction NMDA-Receptor antagonists have rapid antidepressant and antisuicidal properties. However, the antidepressant effect is short lasting raising the question of best maintenance strategy, which is unanswered so far.
E. Kavakbasi, B. T. Baune
doaj +1 more source
Therapeutic environment for esketamine a policy [PDF]
This project aimed to develop a structured policy surrounding the therapeutic environment of esketamine to provide continuity of care and maximize therapeutic benefits while mitigating possible side effects of esketamine. A literature review for the most
Stewart, Sierra
core +1 more source
Esketamine in the treatment of chronic endometriosis-induced pain: a case report [PDF]
Introduction:The pathophysiology of endometriosis-induced pain is complex and current pain management is often inadequate. As a consequence, the quality of life of endometriosis patients is reduced due to persistent and often recurrent severe pain ...
Jansen, F.W. +11 more
core +1 more source
Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce.
Abel (K.A.J.) Busz +16 more
doaj +1 more source
BackgroundWhether nasal administration of esketamine can provide effective analgesia is unclear in patients with acute pain after preoperative CT-guided needle localization.MethodsIn this double-blind, randomized, placebo-controlled trial, patients were ...
Jiangning Xu +7 more
doaj +1 more source

